KLOW Blend 80mg

The KLOW Blend is a fixed-ratio research-supply formulation that combines four peptides into a single lyophilized vial. The vial holds fifty milligrams of GHK-Cu, plus ten milligrams each of BPC-157, TB-500, and KPV. Total peptide content sums to eighty milligrams. The KLOW name derives from the four component initials — KPV, plus the LOW abbreviation that combines GHK and the BPC/TB pairing into a single mnemonic. Each component peptide is also available from Ronin Peptides as a standalone single-compound vial; the blend format pairs the four at convenient working concentrations matching the standalone-vial loadings.

One distinctive feature: per-component loadings in this blend equal the standalone-vial loadings exactly. Buying the KLOW Blend delivers the equivalent of one full vial of each compound in a single reconstitution operation. This contrasts with the Wolverine Stack format, which contributes half the per-component loading.

The blend's lyophilized form takes a characteristic blue-to-blue-violet tint owing to the GHK-Cu Cu(II) chromophore. The other three components — BPC-157, TB-500, and KPV — do not contribute to the visible-spectrum colour. Reconstituted aqueous solutions retain the blue tint at typical research working concentrations.

The compound is supplied as a sealed amber-glass vial under inert gas. Reconstitution with bacteriostatic water is required before any of the four component peptides can be drawn into an insulin syringe. Reconstitution math is per-component: a single 80 mg vial reconstituted with 2 mL of bacteriostatic water yields 25 mg/mL of GHK-Cu, 5 mg/mL of BPC-157, 5 mg/mL of TB-500, and 5 mg/mL of KPV simultaneously — the four peptides share the same diluent volume but contribute distinct working concentrations corresponding to their respective vial loadings.

The four component peptides occupy four non-overlapping mechanism niches across the skin-and-tissue-repair-and-anti-inflammatory research landscape. GHK-Cu has been investigated for ECM remodelling, fibroblast and keratinocyte cellular pathway modulation, antioxidant chemistry, and gene-expression regulation, with the literature anchored by half a century of work since the original Pickart-laboratory characterisation (PMID 11325542, PMID 26236730, PMID 29986520). BPC-157 has been investigated for vascular and angiogenic signalling through VEGFR2 receptor activation and the downstream Akt-eNOS branch, alongside gastric-protection findings (PMID 27847966, PMID 21030672, PMID 38980576). TB-500's parent Thymosin β-4 has been characterised across actin-cytoskeleton dynamics, cell migration, cardiac progenitor mobilisation, and corneal wound-healing (PMID 11579089, PMID 15565145, PMID 27450738). KPV — the C-terminal Lys-Pro-Val tripeptide of α-melanocyte-stimulating hormone — has been investigated for anti-inflammatory effects through cytokine modulation in intestinal-inflammation, ulcerative-colitis, and dermal-inflammation research streams (PMID 18061177, PMID 18092346, PMID 27458604, PMID 28143741).

Across the literature the blend's components have been investigated in combination protocols across dermal, tissue-repair, and combined-mechanism studies. Recent broader peptide-therapy reviews (PMID 41966639, PMID 41490200) cover multiple of the components in the wider research-context. Researchers planning experiments with the four-component blend should consult the most current literature on each component peptide to position findings against the broader mechanism-niche framework.

No regulatory authority — Health Canada, the FDA, the EMA, the TGA, or any equivalent — has cleared any of the four component compounds, or the blend formulation, as a drug for human or veterinary use. GHK-Cu carries cosmetic-ingredient approval under the INCI name Copper Tripeptide-1; cosmetic ingredient approval is regulatorily distinct from drug approval. None of the four compounds are listed as scheduled controlled substances. Ronin Peptides ships the blend exclusively as a research-grade reagent for benchwork. Dosing protocols, treatment regimens, and administration instructions are out of scope and not provided in any form.

The blend's four components engage four molecular niches that do not overlap at the receptor or signalling-pathway level. Investigators studying combined-compound protocols often cite this non-overlap as the rationale for the most-comprehensive Ronin blend format — each compound contributes activity at a distinct molecular target without competing for the same receptor or downstream effector.

GHK-Cu's mechanism centres on Cu(II) carrier function and broad gene-regulatory effects. The Gly-His-Lys tripeptide chelates a single copper-2 ion at a square-planar coordination pocket built from the histidine imidazole nitrogen and adjacent backbone amides. The 2001 Biochimica et Biophysica Acta paper anchored the foundational chelation chemistry (PMID 11325542). The 2018 Pickart-laboratory IJMS review compiled transcriptome-profiling data showing thousands of human genes flagged as differentially expressed under GHK-Cu exposure (PMID 29986520). The 2015 Pickart-laboratory review compiled multiple cellular pathways modulated in skin-regeneration model systems (PMID 26236730).

BPC-157's mechanism centres on VEGFR2 receptor activation in vascular endothelial cells. The 2017 Hsieh paper documented receptor activation and upregulation in vascular endothelium (PMID 27847966); downstream Akt phosphorylation and eNOS signalling raise nitric-oxide output and support new vessel formation. The 2011 Chang paper documented growth-hormone-receptor expression upregulation in tendon fibroblasts (PMID 21030672). The 2024 Inflammopharmacology review compiled the contemporary GI-protection literature (PMID 38980576).

TB-500's mechanism rests on the parent Thymosin β-4's role as principal G-actin-sequestering peptide in mammalian cells. The 2001 ternary-complex JBC paper defined the profilin-actin-thymosin biophysics (PMID 11579089). The 2004 Bock-Marquette Nature paper documented integrin-linked-kinase activation and cardiac repair in mouse models (PMID 15565145). The 2016 Vitamins and Hormones review compiled the parent dermal-healing literature (PMID 27450738).

KPV's mechanism operates differently from the other three components. The Lys-Pro-Val tripeptide is the C-terminal three residues of α-melanocyte-stimulating hormone (α-MSH). KPV retains anti-inflammatory activity attributed to the α-MSH parent through cytokine-modulation pathways, but does so without engaging the melanocortin receptors (MC1R-MC5R) through which the parent hormone signals. A 2008 Gastroenterology paper documented PepT1-mediated cellular uptake of KPV and downstream reduction of intestinal inflammation (PMID 18061177). A 2008 Inflammatory Bowel Diseases paper characterised the melanocortin-derived tripeptide in murine models of IBD (PMID 18092346). A 2016 Cellular and Molecular Gastroenterology and Hepatology paper extended findings to colitis-associated cancer through PepT1-mediated delivery (PMID 27458604). A 2017 Molecular Therapy paper described nanoparticle-based oral delivery of KPV in ulcerative colitis models (PMID 28143741).

The four mechanism niches converge at the broader tissue-and-cellular-response level — vascular signalling (BPC-157), cytoskeletal dynamics (TB-500), Cu(II)-driven ECM remodelling and gene regulation (GHK-Cu), and anti-inflammatory cytokine modulation (KPV) collectively cover an unusually wide range of repair-and-inflammation pathways within a single blend format.

Skin-and-dermal research forms the largest application bracket for combined-compound research with the blend's four components. GHK-Cu's dermal-matrix work (PMID 26236730, PMID 29986520) connects to BPC-157's wound-healing literature (PMID 21030672) and to TB-500's parent dermal-healing review (PMID 27450738), with KPV's anti-inflammatory work (PMID 18092346) adding a complementary niche.

Tissue-repair research more broadly has produced cross-compound findings, with multiple groups having investigated, characterised, and documented the four molecules across overlapping injury models. BPC-157's tendon-repair work (PMID 21030672) connects to TB-500's parent cardiac and corneal repair findings (PMID 15565145), while GHK-Cu's broader regenerative-research framework (PMID 26236730) and KPV's PepT1-mediated anti-inflammatory work (PMID 18061177, PMID 27458604) add complementary mechanism contributions.

Anti-inflammatory and gut-research applications form a stream specific to two of the four components. KPV's research portfolio centres heavily on intestinal inflammation, ulcerative colitis, and IBD models (PMID 18061177, PMID 18092346, PMID 27458604, PMID 28143741). BPC-157's gastric-protection literature, anchored by the 2024 Inflammopharmacology review (PMID 38980576), provides a complementary GI-research foundation. The pairing of these two GI-relevant compounds within KLOW Blend distinguishes the format from Glow Blend (which lacks KPV) for researchers investigating GI-tract-relevant combined protocols.

Translation to human clinical application has been narrower than the breadth of the preclinical literature for any of the four component compounds. Each compound has been studied in isolation; the combined-compound translation lags behind single-compound work. Recent reviews (PMID 41966639, PMID 41490200) compile contemporary framings; investigators consulting these reviews should attend to the regulatory context — none of the four components are approved as drugs in any major jurisdiction. KPV has produced active biomaterial-delivery research, with the 2017 Molecular Therapy nanoparticle paper representing one translation track (PMID 28143741).

Independent groups have studied, examined, and characterised the four molecules across in vitro, ex vivo, and animal-model preparations. The cross-laboratory replication landscape varies by component — BPC-157 and the parent Thymosin β-4 have produced larger replication footprints; GHK-Cu and KPV have produced more focused single-laboratory streams complemented by independent characterisation work in recent years.

The blend contains four distinct compounds at the proportions listed below.

Total peptide loading per vial: 80 mg. Form: lyophilized blue-tinted powder (Cu(II) chromophore from GHK-Cu component). Solubility: bacteriostatic water; sterile water for injection. Storage: sealed amber-glass vial under inert gas. Purity: ≥99% per component by HPLC, verified per batch by Janoshik Analytical against the four expected molecular masses.

Per-batch COA documentation for the blend reports analytical results for each of the four component peptides separately, with four distinct mass-spec peaks corresponding to the four components. Researchers integrating the blend into mass-spec-coupled protocols should expect this four-peak pattern.

Unopened lyophilized vials hold up well under dry ambient storage; usable activity persists for several weeks even without refrigeration. The recommended container is the unopened original vial — keep the seal intact until reconstitution. Refrigeration at 2–8 °C is appropriate once the working timeline extends past a month. A standard freezer at −20 °C handles archival storage; ultra-low storage at −80 °C is rarely needed for typical bench-research timescales.

Keep vials shielded from light, ideally in their original outer packaging. The Cu(II) chromophore is photostable in lyophilized form, but reconstituted aqueous solutions show somewhat accelerated degradation under direct UV exposure. Repeated temperature cycling accelerates degradation noticeably more than steady storage at any single temperature inside the recommended bands — minimise transitions between cold and ambient.

After reconstitution, refrigerate the solution at 2–8 °C without delay. The typical working window is four to six weeks at fridge temperature — the same window as each component compound individually. Past that window, peptide concentration drifts downward through chemical degradation pathways. The 0.9% benzyl alcohol in bacteriostatic water holds back bacterial contamination but does not arrest hydrolysis, oxidation, copper-ligand-dissociation, and aggregation processes accumulating in any aqueous peptide solution. The four components may degrade at slightly different rates; the limiting component is typically GHK-Cu, where loss of the blue Cu(II) chromophore is a useful visual indicator of concentration drift. The BPC-157, TB-500, and KPV components do not contribute to the colour and require COA mass-spec confirmation for status.

When a research timeline extends past six weeks, common practice is splitting the reconstituted solution into single-use volumes and freezing them at −20 °C immediately. Ice-crystal formation during each freeze-thaw cycle inflicts mechanical damage on peptide chains, and pre-splitting eliminates the cumulative loss that comes from thawing one vial multiple times. Thaw individual aliquots overnight in a refrigerator — never at room temperature — and use them within a few days of thaw.

The reconstituted product should be visually transparent with a characteristic blue tint and no suspended particulate. Discard any vial showing turbidity, suspended particulate, yellowing, decolourisation, or visible precipitate. The diluent of choice is USP-grade bacteriostatic water containing 0.9% benzyl alcohol — see the bacteriostatic water product page for reconstitution-grade water.

The KLOW Blend is the largest of Ronin's three blend formats by total peptide content and the only one that includes the KPV anti-inflammatory tripeptide. Researchers focused on the dermal and tissue-repair niches without anti-inflammatory KPV use the Glow Blend; researchers focused exclusively on the BPC-157 + TB-500 tissue-repair pair use the Wolverine Stack. Each component compound is also available as a standalone single-compound vial.

Reconstituting the KLOW Blend follows the same procedure as a single-compound vial, with one important difference: the resulting solution contains four peptides at four distinct concentrations corresponding to their per-vial loadings. A single 80 mg vial reconstituted with 2 mL of bacteriostatic water yields the following per-component working concentrations:

• GHK-Cu: 25 mg/mL (50 mg / 2 mL) = 25,000 mcg/mL
• BPC-157: 5 mg/mL (10 mg / 2 mL) = 5,000 mcg/mL
• TB-500: 5 mg/mL (10 mg / 2 mL) = 5,000 mcg/mL
• KPV: 5 mg/mL (10 mg / 2 mL) = 5,000 mcg/mL

Other diluent volumes scale linearly. A 5 mL reconstitution gives GHK-Cu at 10 mg/mL plus the other three at 2 mg/mL. A 10 mL reconstitution gives GHK-Cu at 5 mg/mL plus the other three at 1 mg/mL. Researchers planning experiments should choose the diluent volume based on which component's working concentration anchors the experimental design.

Reconstitution procedure:

1. Bring both vials — peptide blend and bacteriostatic water — to room temperature before opening.
2. Sanitise both rubber stoppers with an alcohol swab.
3. Pull the chosen diluent volume into a sterile transfer syringe.
4. Direct the water against the inner wall of the peptide vial as it is injected — never onto the lyophilized cake, since direct impact foams the solution and denatures peptide at the air-water interface.
5. Invert slowly or swirl gently until everything dissolves. Do not vortex; do not shake.
6. Refrigerate at 2–8 °C the moment reconstitution completes.

A finished preparation should be visually transparent with a characteristic blue tint and no suspended particulate. The blue colour confirms intact Cu(II) chelation on the GHK-Cu component; loss of colour during storage signals copper-ligand dissociation. If the solution is hazy, contains visible material, or has decolourised, treat it as degraded and discard.

For dose-volume calculations on insulin syringes, use the Ronin peptide reconstitution calculator. The calculator handles per-component concentration arithmetic for blend formats.

Per-component dose ranges in published preclinical research differ across the four compounds. GHK-Cu has been studied across cell-culture concentrations in the nanomolar to low-micromolar range. BPC-157 has been examined in animal models at 6 to 50 micrograms per kilogram across multiple routes. TB-500's parent Thymosin β-4 has been documented at micrograms-per-kilogram parenteral dosing. KPV has been characterised in rodent IBD models at micrograms-to-milligrams-per-kilogram oral and intraperitoneal dosing. These figures are research-reference only — Ronin Peptides does not provide dosing recommendations or administration instructions for any non-laboratory purpose.

1. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation. J Mol Med. 2017;95(3):323-333. PMID: 27847966 | doi:10.1007/s00109-016-1488-y
2. Chang CH et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing. J Appl Physiol. 2011;110(3):774-780. PMID: 21030672 | doi:10.1152/japplphysiol.00945.2010
3. Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology. 2024;32(5):3119-3161. PMID: 38980576 | doi:10.1007/s10787-024-01499-8
4. Conato C et al. Copper complexes of glycyl-histidyl-lysine and two of its synthetic analogues: chemical behaviour. Biochim Biophys Acta. 2001;1526(2):199-210. PMID: 11325542 | doi:10.1016/s0304-4165(01)00127-1
5. Pickart L et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. PMID: 26236730 | doi:10.1155/2015/648108
6. Pickart L et al. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520 | doi:10.3390/ijms19071987
7. Yarmola EG et al. Formation and implications of a ternary complex of profilin, thymosin beta 4, and actin. J Biol Chem. 2001;276(49):45555-45563. PMID: 11579089 | doi:10.1074/jbc.M105723200
8. Bock-Marquette I et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration. Nature. 2004;432(7016):466-472. PMID: 15565145 | doi:10.1038/nature03000
9. Kleinman HK et al. Thymosin β4 Promotes Dermal Healing. Vitam Horm. 2016;102:251-275. PMID: 27450738 | doi:10.1016/bs.vh.2016.04.005
10. Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. PMID: 18061177 | doi:10.1053/j.gastro.2007.10.026
11. Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. PMID: 18092346 | doi:10.1002/ibd.20334
12. Viennois E et al. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV. Cell Mol Gastroenterol Hepatol. 2016;2(3):340-357. PMID: 27458604 | doi:10.1016/j.jcmgh.2016.01.006
13. Xiao B et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. PMID: 28143741 | doi:10.1016/j.ymthe.2016.11.020
14. Mendias CL et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries. Sports Med. 2026. PMID: 41966639 | doi:10.1007/s40279-026-02437-0
15. Rahman OF et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026. PMID: 41490200 | doi:10.5435/JAAOSGlobal-D-25-00236